Novo Nordisk Cuts Outlook Amid Slowing Demand for GLP-1 Drugs
Novo Nordisk scaled back its full-year guidance after reporting weaker-than-expected third-quarter results, signaling growing challenges in the weight-loss drug market. The Danish pharmaceutical giant now anticipates operating profit growth of 4%-7% and sales expansion of 8%-11%, down from previous projections of 4%-20% and 8%-14%, respectively.
Wegovy sales grew 18% to $3.13 billion, missing estimates, while Ozempic revenue ROSE 3% to $4.73 billion, slightly exceeding expectations. The company attributed the revised outlook to softening demand for its GLP-1 treatments amid intensifying competition and pricing pressures.
This marks Novo Nordisk's fourth downward revision in 2025, reflecting eroding dominance in a sector it once led. The disappointing performance sent U.S.-listed shares lower as investors reassessed growth prospects for the weight-loss drug category.
